Psyence Biomedical (PBM) Stock Price, News & Analysis

Company Overview

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Key Stats

• Today's Range: $4.19 to $4.37
• 50-Day Range: $2.71 to $4.47
• 52-Week Range: $1.92 to $34.63
• Volume: 14,674 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $9.64 million
• P/E Ratio: 0.17
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Psyence Biomedical Stock Analysis - MarketRank™

Psyence Biomedical scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Psyence Biomedical has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Psyence Biomedical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Psyence Biomedical is 0.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of Psyence Biomedical is 0.17, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.57.

Price to Book Value per Share Ratio

Psyence Biomedical has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.65% of the float of Psyence Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Psyence Biomedical has a short interest ratio ("days to cover") of 0.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Psyence Biomedical has recently decreased by 61.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Psyence Biomedical does not currently pay a dividend.

Dividend Growth

Psyence Biomedical does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.43

News Sentiment

Psyence Biomedical has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Psyence Biomedical this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for PBM on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

1 people have added Psyence Biomedical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Psyence Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.60% of the stock of Psyence Biomedical is held by insiders.

Percentage Held by Institutions

77.44% of the stock of Psyence Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/22/2026
• Today: 8/28/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PBM
• Previous Symbol: NASDAQ:PBM
• CIK: 1985062
• Web: www.psyencebiomed.com
• Phone: 510-214-3750
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.17
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.62
• Quick Ratio: 14.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.39 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 2,290,000
• Free Float: 2,210,000
• Market Cap: $9.60 million
• Optionable: N/A
• Beta: 1.66